Tempus AI News - August 2026
🟢 Tempus AI is trading 10.29% up today as Moderna vaccine results strengthen Personalis deal confidence
Tempus AI is trading $67.55 (+10.29%) as investors connect positive Phase 3 results for Moderna’s personalized cancer vaccine with Personalis, which Tempus AI...
🟢 Tempus AI is trading 6.29% up today as Merck–Moderna trial success validates Personalis-linked sequencing
Tempus AI is trading 6.29% up now at $65.11 as investors continue rewarding Wednesday’s landmark Merck–Moderna cancer-vaccine trial results. - Phase 3 success...
Tempus AI Rockets 22% on a Cancer Vaccine Breakthrough — But Can a Single Trial Justify a $1.5 Billion Bet?
Shares of Tempus AI surged 22% to $60.23 Wednesday after a landmark clinical trial handed the company an unexpected windfall of validation. A personalized...
Tempus AI Surges, as Cancer Vaccine Success Validates $1.5B Personalis Deal
Tempus AI shares surged more than 20% on Wednesday. The rally followed news that a personalized mRNA cancer vaccine from Merck and Moderna succeeded in a...
🟢 Tempus AI is trading 12.64% up today; no clear catalyst identified
Tempus AI is trading 12.64% up at $55.40, with no clear company-specific catalyst identified for August 19, 2026. - Latest listed releases were the August 4...
🟢 Tempus AI is trading 13.19% up in pre-market despite no identified catalyst
Tempus AI is trading 13.19% up at $55.87 after no clear company-specific announcement was identified for August 19, 2026. - The latest listed company releases...
Tempus AI Validates PRISM2 Model, Outperforming Rivals in Nature Medicine Study
Tempus AI announced a new study in Nature Medicine validating its PRISM2 AI-powered pathology model. The model, developed in collaboration with Microsoft,...